high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Published Date: 12 Apr 2024

71 percent ORR that increased over time, along with a good safety record when using linvoseltamab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

2.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

3.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

4.

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

5.

iPSC-based vaccines: A new hope for preventing and treating colorectal cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot